Study Title

telixpharmaceuticals

A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer

Study Details

Description:

This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592). TLX592 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours, therefore this study has been designed to assess the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation dosimetry of 64Cu-TLX592.

Sponsor:

Telix Pharmaceuticals

Contacts:

Nat Lenzo, MD

nat.lenzo@genesiscare.com

+61 02 8236 3300

Tracey Brown, PhD

tracey.brown@telixpharma.com

0412010104

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Nat Lenzo, MD for more information.

+61 02 8236 3300

nat.lenzo@genesiscare.com